Cancer Institute Clinical Trials Lymphoma-Leukemia-Myeloma

Lymphoma

#90569 NCT00608361
Title:
Dasatinib in Treating Patients with Metastatic or Unresectable Solid Tumor or Lymphoma
Study Location: Temple Main Campus

#120319 NCT01611090
Title: Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study Location: Temple Main Campus

Leukemia

#50148 NCT00074282
Title: Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or REfractory Patients with Chronic Lymphocytic Leukemia
Study Location: Temple Main Campus

#120117 NCT01580228
Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Leukemia
Study Location: Temple Main Campus

#120319 NCT01611090
Title: Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study Location: Temple Main Campus

Myeloma

#120127 NCT01568866
Title: A Randomized, Open-label, Phase III Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma (ENDEAVOR)
Study Location: Temple Main Campus

For more information or to enroll in a study please call: 1-254-724-5407


Print
Text Size
A
A
A